CYTOKINETICS SHARES RISE 36% PREMARKET AFTER LATE-STAGE STUDY DATA SHOWS CO'S DRUG MORE EFFECTIVE FOR HEART DISEASE SYMPTOMS THAN STANDARD-OF-CARE

Reuters · 09/02/2025 08:03

Please log in to view news